Summary
[Updated]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with
relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic
syndromes and to assess: i) safety and tolerability and ii) preliminary efficacy of the
combination of ONO-7475 and venetoclax in patients with relapsed or refractory acute myeloid
leukemia.